An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies
Categories (click each to see list of all clinical trials associated with that category): Lymphoma/CLL (ONC)
Current Status: Open
Phase: III (Cancer Control)
Principal Investigator: Bociek, R Gregory
Eligibility: https://clinicaltrials.gov/ct2/show/NCT04170283?term=NCT04170283&draw=2&rank=1#eligibility
Summary
Primary Objective
To evaluate the long-term safety of zanubrutinib, as monotherapy or in combination, in patients with B-cell
malignancies who participated in a BeiGene parent study for zanubrutinib
Secondary Objectives
To evaluate the long-term efficacy of zanubrutinib, as monotherapy or in combination, by measuring the following:
o Progression-free survival (PFS)
o Duration of response (DOR)
o Overall survival (OS)